Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Pevifoscorvir sodium demonstrated profound antiviral activity in untreated HBeAg+ subjects, regardless of baseline ALT level

Wednesday, May 27, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Pevifoscorvir sodium has demonstrated significant antiviral activity in untreated HBeAg+ subjects, showing effectiveness regardless of baseline ALT levels. This finding suggests a promising potential for the treatment of chronic HBV infection. The results highlight the drug's capability to address a critical need in managing hepatitis B.
Price reaction · baseline $5.74 (2026-05-26 close) · hit pre-market · 7 other ALGS headline(s) in the window, move may be shared
day 0 close · peak
-2.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Pevifoscorvir sodium shows strong antiviral activity.
  • Effective in untreated HBeAg+ subjects.
  • Results are consistent across varying baseline ALT levels.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is Pevifoscorvir sodium?

Pevifoscorvir sodium is an antiviral medication targeting chronic HBV infection.

Who were the subjects in the study?

The study involved untreated HBeAg+ subjects.

Does baseline ALT level affect Pevifoscorvir's efficacy?

No, Pevifoscorvir's antiviral activity is effective regardless of baseline ALT levels.

What condition does Pevifoscorvir sodium aim to treat?

It aims to treat chronic hepatitis B virus (HBV) infection.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare Pevifoscorvir HBeAg+ chronic HBV antiviral treatment ALT levels
Last updated: May 27, 2026

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →